Verisk Analytics, Inc. Contingent consideration fair value adjustments decreased by 82.8% to $1.10M in Q1 2026 compared to the prior quarter.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$22.00M | $0.00 | $0.00 | $0.00 | $0.00 | -$1.10M | $0.00 | -$1.60M | $0.00 | $6.40M | $1.10M |
| QoQ Change | — | — | — | — | — | — | — | — | +100.0% | — | — | — | — | +100.0% | — | +100.0% | — | -82.8% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +100.0% | — | — | — | — | — | +681.8% | — |